190 related articles for article (PubMed ID: 35931197)
1. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
3. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
Falls BA; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
[TBL] [Abstract][Full Text] [Related]
4. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
[TBL] [Abstract][Full Text] [Related]
5. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
6. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
[TBL] [Abstract][Full Text] [Related]
7. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
9. Differential Signaling Profiles of MC4R Mutations with Three Different Ligands.
Paisdzior S; Dimitriou IM; Schöpe PC; Annibale P; Scheerer P; Krude H; Lohse MJ; Biebermann H; Kühnen P
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059383
[TBL] [Abstract][Full Text] [Related]
10. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
[TBL] [Abstract][Full Text] [Related]
11. The melanocortin pathway and control of appetite-progress and therapeutic implications.
Baldini G; Phelan KD
J Endocrinol; 2019 Apr; 241(1):R1-R33. PubMed ID: 30812013
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
13. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.
Heyder NA; Kleinau G; Speck D; Schmidt A; Paisdzior S; Szczepek M; Bauer B; Koch A; Gallandi M; Kwiatkowski D; Bürger J; Mielke T; Beck-Sickinger AG; Hildebrand PW; Spahn CMT; Hilger D; Schacherl M; Biebermann H; Hilal T; Kühnen P; Kobilka BK; Scheerer P
Cell Res; 2021 Nov; 31(11):1176-1189. PubMed ID: 34561620
[TBL] [Abstract][Full Text] [Related]
14. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M
Front Immunol; 2019; 10():2312. PubMed ID: 31636637
[TBL] [Abstract][Full Text] [Related]
15. Molecular cloning, tissue distribution, and pharmacological characterization of melanocortin-4 receptor in spotted scat, Scatophagus argus.
Li JT; Yang Z; Chen HP; Zhu CH; Deng SP; Li GL; Tao YX
Gen Comp Endocrinol; 2016 May; 230-231():143-52. PubMed ID: 27080551
[TBL] [Abstract][Full Text] [Related]
16. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
[TBL] [Abstract][Full Text] [Related]
17. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat.
Mul JD; van Boxtel R; Bergen DJ; Brans MA; Brakkee JH; Toonen PW; Garner KM; Adan RA; Cuppen E
Obesity (Silver Spring); 2012 Mar; 20(3):612-21. PubMed ID: 21527895
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response.
Roubert P; Dubern B; Plas P; Lubrano-Berthelier C; Alihi R; Auger F; Deoliveira DB; Dong JZ; Basdevant A; Thurieau C; Clément K
J Endocrinol; 2010 Nov; 207(2):177-83. PubMed ID: 20696697
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.
Chapman KL; Kinsella GK; Cox A; Donnelly D; Findlay JB
J Mol Biol; 2010 Aug; 401(3):433-50. PubMed ID: 20600126
[TBL] [Abstract][Full Text] [Related]
20. G-protein-independent coupling of MC4R to Kir7.1 in hypothalamic neurons.
Ghamari-Langroudi M; Digby GJ; Sebag JA; Millhauser GL; Palomino R; Matthews R; Gillyard T; Panaro BL; Tough IR; Cox HM; Denton JS; Cone RD
Nature; 2015 Apr; 520(7545):94-8. PubMed ID: 25600267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]